


### Cyanobacteria-based payload platform - a unique potential for targeted cancer therapies

#### Company

- As a pioneer & global leader in **applied R&D on cyanobacteria**, we offer novel drug leads, based on superior natural products (NP) for direct or ADC-based utilization in **anti-cancer drug development**
- **Modern lab and production infrastructure:** state-of-the-art equipment for drug development, cultivation, downstream processing, analytics
- **Core competencies:** unique strain & compound collection, patent-protected assets and methods, from natural-product-based drug discovery and development to industrial production

#### Anti-Cancer Payload Platform

- Cyanobacteria are well-known for their **highly potent payloads** for ADCs\* (e.g. Auristatins, Cryptophycins)
- Worldwide largest cyanobacteria strain collection with **> 5,000 new compounds, > 300 anti-cancer hits**
  - **Many new payload classes** incl. new modes of action, beneficial safety profiles, IC<sub>50</sub> values down to 10 pM
  - Patented modification of known & novel peptide toxins towards **uniquely designed structures**, incl. site-directed click chemistry introduction for MAb\* linkage and labelling
  - **Biological production system** for straight-forward production scale-up



#### Products

- **Patented New Microcystin Payloads** (off the shelf)
  - Each variant with multifactorial mode of action (inhibition of two protein phosphatases + ROS\*)
  - Proven efficacy as ADC in picomolar range with favorable safety profile (non-toxic for healthy cells)
  - Customized manufacturing at milligram scale
- **R&D Services**
  - Microcystin libraries for solid + non-solid tumors with variable conjugation and click chemistries
  - Additional clickable payload toxins: Nodularins, Cryptophycins, Largazoles, Apratoxins and more
  - Production strain development and scale-up for clinical-scale GMP manufacturing

#### Proposal to Pharma

##### R&D Cooperation

For your oncology or other drug research activities, we can offer our unique payload platform and co-develop patentable leads linked to a target-specific MAb of choice.

Please contact us for further information and an explorative discussion:

Cyano Biotech GmbH  
Magnusstr. 11, 12489 Berlin  
[info@cyano-biotech.com](mailto:info@cyano-biotech.com)  
+49 (30) 6392 4481  
[www.cyano-biotech.com](http://www.cyano-biotech.com)

\*ADC: antibody-drug conjugate  
\*ROS: reactive oxygen species

\* MAb: monoclonal antibody